Shots:
- SOFIE Biosciences has dosed the first patient with [18F]FAPI-74, a fluorine-18 labeled radiopharmaceutical, in the P-III (FAPI-GO) trial for the diagnosis of GI cancers
- The trial will assess the clinical utility of [¹⁸F]FAPI-74 PET/CT over 24mos. in the detection of metastatic disease in 200 adults with gastroesophageal cancer across 18 sites
- Another P-III (FAPI-PRO) study, launching Dec 2025, will evaluate the clinical utility of [¹⁸F]FAPI-74 PET/CT to detect metastatic disease in adults with pancreatic ductal adenocarcinoma
Ref: PRnewswire | Image: SOFIE Biosciences | Press Release
Related News: Mabwell Doses First Patient in P-II Trial of 9MW3811 for Pathological Scarring
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
